新闻中心
The “Golden Duo” of Cancer Immunotherapy: PD-1 & IL-2 Dual-Target Reporter Cells
Kyinno Biotechnology
25.12.2025
Kyinno Biotechnology Announces USD 35M Series B Financing, Focusing on Dual/Multispecific Antibody Innovation
Kyinno Biotechnology
21.12.2025
Dual-Target ADC Achieves “1+1>2” Synergistic Killing: Four Core Dimensions Are Key
Kyinno Biotechnology
21.12.2025
ASGR1 Overexpression Cell Lines Drive IgA Nephropathy and Breakthroughs in Multidisciplinary Drug R&D
Kyinno Biotechnology
21.12.2025
Rapid Tracking, Precise Degradation: ESR1-HiBiT-KI Cell Line Breaks Through the Challenge of Breast Cancer Drug Resistance
Kyinno Biotechnology
12.12.2025
CD8, From Immune Sentinel to Anticancer Target: Unpacking the Therapeutic Revolution of the Core T Cell Receptor
Kyinno Biotechnology
08.12.2025
WRN MutCell Platform, Advancing Precision Resistance Research · Driving New Drug Breakthroughs
Kyinno Biotechnology
05.12.2025
WRN MutCell Platform, Advancing Precision Resistance Research · Driving New Drug Breakthroughs
Kyinno Biotechnology
01.12.2025